Hematopoietic growth factors in cancer chemotherapy.
Hematopoietic growth factors have made a significant impact on the treatment of cancer, primarily in the prevention of infections associated with chemotherapy-induced neutropenia, in progenitor cell transplantation, in chemotherapy-induced thrombocytopenia, and in chemotherapy-induced anemia. As seen with this review, our basic understanding of hematopoietic growth factors and their clinical potential continue to expand. Work will need to continue, especially with the new thrombopoietic factors, megakaryocyte growth and developing factor, thrombopoietin, and IL-11, to fully categorize their biology and clinical characteristics.
Crawford
J
J
Amgen Inc., Thousand Oaks, CA 91320-1789, USA.
Foote
M
M
Morstyn
G
G
D004999:Amifostine / Q000627:therapeutic use; D000818:Animals; D004921:Erythropoietin / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D017370:Interleukin-11 / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D019089:Stem Cell Factor / Q000627:therapeutic use
D016298:Hematopoietic Cell Growth Factors; D017370:Interleukin-11; D019089:Stem Cell Factor; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D004999:Amifostine